Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia
Heart Rhythm · 2025
DOI: 10.1016/j.hrthm.2024.09.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2025. Verfasst von Oliver M Moore und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Integrative Physiology, Baylor College of Medicine, Hous…. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Ryanodine Receptor Calcium Release Channel, Myocytes, Cardiac, Tetracaine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: NHLBI NIH HHS, American Heart Association, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia disorder associated with lethal arrhythmias. Most CPVT cases are caused by inherited variants in the gene encoding ryanodine receptor type 2 (RYR2). OBJECTIVE: The goal of this study was to investigate the structure-activity relationship of tetracaine derivatives and to test a lead compound in a mouse model of CPVT. METHODS: We synthesized >200 tetracaine derivatives and characterized 11 of those. The effects of these compounds on Ca2+ handling in cardiomyocytes from R176Q/+ mice was tested with confocal microscopy. The effects of lead compound MSV1302 on arrhythmia inducibility and cardiac contractility were tested by programmed electrical stimulation and echocardiography, respectively. Plasma and microsomal stability and cytotoxicity assays were also performed. RESULTS: Ca2+ imaging revealed that 3 of 11 compounds suppressed sarcoplasmic reticulum Ca2+ leak through mutant RyR2. Two compounds selected for further testing exhibited a half-maximal effective concentration of 146 nM (MSV1302) and 49 nM (MSV1406). Whereas neither compound altered baseline electrocardiogram intervals, only MSV1302 suppressed stress- and pacing-induced ventricular tachycardia in vivo in R176Q/+ mice. Echocardiography revealed that the lead compound MSV1302 did not negatively affect cardiac inotropy and chronotropy. Finally, compound MSV1302 did not block INa, ICa,L, or IKr; it exhibited excellent stability in plasma and microsomes, and it was not cytotoxic. CONCLUSION: Structure-activity relationship studies of second-generation tetracaine derivatives identified lead compound MSV1302 with a favorable pharmacokinetic profile. MSV1302 normalized aberrant RyR2 activity in vitro and in vivo, without altering cardiac inotropy, chronotropy, or off-target effects on other ion channels. This compound may be a strong candidate for future clinical studies to determine its efficacy in CPVT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas; Department of Neuroscience, Baylor College of Medicine, Ho…
- Department of Chemistry, Portland State University, Portland, Oregon.
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas.
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas; Division of Cardiology, Department of Internal Medicine, T…
- Division of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Förderung
- NHLBI NIH HHS
- American Heart Association
- National Institutes of Health
- Baylor College of Medicine
- Foundation for the National Institutes of Health
Zitieren
APA
Moore, O. M., Sibrian-Vazquez, M., Navarro-Garcia, J. A., Aguilar-Sanchez, Y., Turkieltaub-Paredes, M. R., Lahiri, S. K., Ni, L., Word, T. A., Miyake, C. Y., Strongin, R. M., & Wehrens, X. H. T. (2025). Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.09.062
Vancouver
Moore OM, Sibrian-Vazquez M, Navarro-Garcia JA, Aguilar-Sanchez Y, Turkieltaub-Paredes MR, Lahiri SK, et al. Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2024.09.062
BibTeX
@article{Moore2025,
author = {Moore, Oliver M and Sibrian-Vazquez, Martha and Navarro-Garcia, Jose Alberto and Aguilar-Sanchez, Yuriana and Turkieltaub-Paredes, Mara R and Lahiri, Satadru K and Ni, Li and Word, Tarah A and Miyake, Christina Y and Strongin, Robert M and Wehrens, Xander H T},
title = {Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia},
journal = {Heart Rhythm},
year = {2025},
doi = {10.1016/j.hrthm.2024.09.062}
}
EUVIMED